Scholarlink

<p>While many of the drugs used to treat asthma or cardiovascular disease can potentially worsen the other condition, some are beneficial. Evidence and guidance on treatments for patients with comorbid asthma and cardiovascular disease is limited. Inhaled corticosteroids, the preferred treatment for asthma, should still be used, as the risk of increasing overall cardiovascular adverse events (AEs) is low. For cardiovascular disease management, cardioselective over nonselective β-adrenergic receptor blockers, and angiotensin II type 1 receptor blockers over angiotensin-converting enzyme inhibitors should be considered, as they are associated with a lower risk of pulmonary AEs. Additionally, statins may reduce pulmonary AEs.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Consider the cardiovascular and pulmonary effects of treatments in patients with both asthma and cardiovascular disease

  • 期刊论文

  • 发表日期：

    2025年6月1日

查看全文
  • Simon Fung

摘要

While many of the drugs used to treat asthma or cardiovascular disease can potentially worsen the other condition, some are beneficial. Evidence and guidance on treatments for patients with comorbid asthma and cardiovascular disease is limited. Inhaled corticosteroids, the preferred treatment for asthma, should still be used, as the risk of increasing overall cardiovascular adverse events (AEs) is low. For cardiovascular disease management, cardioselective over nonselective β-adrenergic receptor blockers, and angiotensin II type 1 receptor blockers over angiotensin-converting enzyme inhibitors should be considered, as they are associated with a lower risk of pulmonary AEs. Additionally, statins may reduce pulmonary AEs.